Online Program Home
My Program

Abstract Details

Activity Number: 612
Type: Contributed
Date/Time: Wednesday, August 3, 2016 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #318708 View Presentation
Title: Adaptive Dose Modification for Phase I Clinical Trials
Author(s): Yiyi Chu* and Haitao Pan and Ying Yuan
Companies: The University of Texas School of Public Health and MD Anderson Cancer Center and MD Anderson Cancer Center
Keywords: Dose finding ; Phase I trials ; Dose modification ; MTD ; Nonparametric estimation
Abstract:

Most phase I dose-finding methods in oncology aim to find the maximum-tolerated dose (MTD) from a set of prespecified doses. However, in practice, due to a lack of understanding of the true dose-toxicity relationship, it is likely that none of these prespecified doses is equal or reasonably close to the true MTD. To handle this issue, we propose an adaptive dose modification (ADM) method that can be coupled with any existing dose-finding method to adaptively add a dose, when it is needed, during the course of dose finding. To reflect clinical practice, we divide the toxicity probability into three regions: underdosing, acceptable and overdosing regions. We adaptively add a dose whenever the observed data suggest that none of the investigational doses is likely to be located in the acceptable region. The added dose is estimated via a nonparametric dose-toxicity model based on local polynomial regression. The simulation study shows that ADM outperforms the similar existing method, with more precise added doses. We applied ADM to a phase I cancer trial.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association